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Crohn’s disease and ulcerative colitis are the two major forms of chronic relapsing inflammatory disorders of
the human intestines collectively referred to as inflammatory bowel disease (IBD). Though a complex set of
autoinflammatory disorders that can be precipitated by diverse genetic and environmental factors, a feature
that appears common to IBD pathogenesis is a dysregulated effector T cell response to the commensal
microbiota. Due to the heightened effector T cell activity in IBD, developmental and functional pathways
that give rise to these cells are potential targets for therapeutic intervention. In this review, we highlight recent
advances in our understanding of effector T cell biology in the context of intestinal immune regulation and
speculate on their potential clinical significance.Introduction
CD4+ T cells are selected in the thymus to generate a broad
repertoire of clonal specificities that enable peripheral immune
surveillance of antigens that are presented by the MHC II path-
way. This allows for protective antipathogenic T cell responses
to microbial threats that enter antigen-presenting cells (APCs)
primarily through phagocytic and pinocytotic routes, but it also
holds the potential for deleterious responses to host self-
antigens and components of the commensal microbiota. Com-
mensal bacteria comprise the largest number and diversity of
extracellular, ‘‘nonself’’ antigens that can be encountered by
CD4+ T cells, and by far, the greatest number of these resides
in the intestinal tract (Ley et al., 2006). Despite robust
innate barrier and innate immune mechanisms that largely
sequester the gut commensal microbiota from the CD4+ T cell
compartment, on-going ‘‘sampling’’ of the flora occurs, reflected
in the representation of specificities to antigens of the com-
mensal flora in the peripheral T cell repertoire (Lathrop et al.,
2008).
In the setting of immune homeostasis, both effector and regu-
latory CD4+ T cells (Tregs) that recognize enteric microbial anti-
gens are highly enriched in the gut-associated lymphoid tissues
(GALT). Realization that the normal CD4+ T cell repertoire
includes specificities that can mount—as well as contain—
inflammatory responses to the microbiota came from ground-
breaking studies demonstrating that the transfer into immuno-
deficient mice of normal CD4+ T cells depleted of endogenous
regulatory cells resulted in IBD (Morrissey et al., 1993; Powrie
et al., 1993) and opened the door to much of our current under-
standing of T cell regulation of innate and adaptive immune
responses to the enteric microbiota. As the organ dedicated to
nutrient uptake, however, the intestines also contain a diversity
of dietary antigens that pass through the lumen on a daily basis.
Remarkably, then, despite T cell receptor specificities directed
against ingested food and commensal microbial antigens,
immune interactions in the intestines are normally dominated
by regulatory activities, such that a perfectly mutualistic relation-
ship is maintained with the intestinal microbiota and aberrant
effector CD4+ T cell responses to commensal antigens are
comparatively rare.In spite of a dominant system of intestinal immune regulation,
spontaneous inflammation still develops in the intestines of
about 1 in 1000 individuals in the developed world. It is likely
that multiple factors and events must intersect to disrupt the
robust system of immune tolerance that has evolved to enable
homeostatic coexistencewith the intestinal microbiota.Whereas
breakdowns in intrinsic barrier and innate immune system func-
tions may initiate IBD, it is evident that effector T cells of the
adaptive immune system figure prominently in sustaining
disease and are probably essential to disease chronicity. The
attributes of immune memory intrinsic to CD4+ T cells, coupled
with the broad antigenic pool represented in a commensal
microbiota that can not be effectively cleared, set the stage
for chronic, organ-specific inflammation that is characteristic
of many autoimmune disorders. Accordingly, a better under-
standing of the developmental and functional pathways of
effector T cells that are involved in IBD pathogenesis is para-
mount to improved therapeutics aimed at interrupting the cycle
of immune inflammation they propagate.
The two most prevalent forms of these diseases, Crohn’s
disease (CD) and ulcerative colitis (UC), can have similar clinical
presentations, marked by abdominal pain, bloody diarrhea,
weight loss, fever, and fatigue, but differ with respect to histo-
pathologic features, distribution of involvement along the
gastrointestinal axis, risk of associated malignancy, and in
some cases, treatment options. Crohn’s Disease is a chronic
relapsing inflammatory disorder that has historically been con-
sidered a Th1-mediated disease. However, recent discovery of
the Th17 pathway has prompted a reassessment of whether
Th1 cells are pathogenic, as key molecules associated with
the development, function, and maintenance of Th17 cells are
upregulated in patients with CD compared to healthy subjects.
In contrast to the T cell populations associated with CD, UC is
generally considered a ‘‘Th2-like’’ disease due to the presence
of elevated Th2-type cytokines in lesional tissue from UC
patients. IL-13 appears to be the predominant T cell-derived
cytokine in UC, along with IL-5; IL-4 is typically not prominent.
Although classical ab TCR-expressing effector T cells likely
play a role at least early in the pathogenesis of UC, natural
killer T (NKT) cells also contribute, a view supported byImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 389
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Figure 1. Mechanisms Inhibiting the
Development and Local Function of
Intestinal Effector CD4+ T Cells
The intestinal epithelium serves as a physical
barrier between the intestinal lumen and the lamina
propria. Intestinal epithelial cells (IECs) secrete
antimicrobial peptides, and goblet cells (data not
shown) secrete mucous that forms a barrier on
the epithelial surface. IECs sense microbe-derived
substances and respond with production of anti-
inflammatory cytokines such as TSLP, IL-25,
TGF-b, and IL-10. IL-10, which is produced by
multiple cell types in the intestines, downregulates
APC expression of MHC II, adhesion molecules
(e.g., ICAM-1), costimulatory molecules (e.g.,
CD80 and CD86), and proinflammatory cytokines
(e.g., IL6, IL-23, or IL-12), thereby inhibitingeffector
T cell (TE) activation. Both IL-10 and TGF-b can
induce high amounts of the negative regulator
CD200 receptor (CD200R) on tissuemacrophages
in the small intestine. As a product of effector T cell
lineages, IL-10 can also act in an autocrinemanner
to downregulate effector T cell responses. Locally
activated TGF-b suppresses both the develop-
ment and function of effector T cells via APC-
and/or T cell-directed mechanisms and promotes
iTreg (TR) development (in the absence of proin-
flammatory factors). Active TGF-b also promotes B cell immunoglobulin (Ig) isotype class switching, resulting in the secretion of flora-reactive IgA, which is trans-
located across IECs in association with J-chain into the intestinal lumen, thereby sequestering bacterial antigens from mucosal APCs.experimental evidence from animal models (Fuss and Strober,
2008).
Mechanisms Limiting Effector T Cell Development
and Function in the Normal Intestine
The bulk of effector CD4+ T cells represented in the normal
immune repertoire are distributed in the gut-associated
lymphoid tissues (GALT), particularly in the lamina propriae and
lymphoid follicles of the small and large intestines. The number
and activity of intestinal T cells are normally controlled by a care-
fully orchestrated regulatory system comprised of multiple cell
types and regulatory molecules, which act to ensure that intes-
tinal immune homeostasis is the default pathway and sponta-
neous inflammation is an anomaly. The pathways utilized can
be loosely grouped into mechanisms that (1) sequester the com-
mensal microbiota within the intestinal lumen, thereby limiting
contact of microbes with the intestinal epithelium, as well as
innate and adaptive immune cells (Duerkop et al., 2009); (2)
restrict activation of innate immune cells exposed to commensal
microbial products to limit proinflammatory cytokine responses
that favor induction of effector T cell responses (Strober, 2009);
(3) tolerize the adaptive immune system to the commensal
microbiota by promoting the differentiation of regulatory rather
than effector T cells (Barnes and Powrie, 2009); and (4) directly
inhibit effector T cell differentiation or function (Figure 1).
Despite these robust regulatory mechanisms, the intestines of
genetically susceptible individuals still become spontaneously
inflamed. It is now clear that there aremultiple pathways to intes-
tinal inflammation, and increasingly, subsets of UC or CD are
being identified. However, excessive or inadequately controlled
CD4+ T cell responses feature prominently in the disease
cascade, such that CD4+ T cells isolated from diseased patients
produce much higher amounts of proinflammatory effector cyto-
kines than cells isolated from healthy patients. The combination
of T cell hyperactivation and an accompanying breakdown in390 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.T cell-mediated regulation set the stage for T cell-associated
perpetuation of inflammation.
Overview of Effector CD4+ T Cell Subsets
There are currently three established subsets of effector CD4+
T cells, Th1, Th2, and Th17, each of which can be detected in
one or another variant of IBD. Cytokines derived from innate
immune cells are dominant in initiating the transcriptional
programs that specify effector cell differentiation, and key cyto-
kine products of each lineage are crucial for lineage self-preser-
vation, through positive-feedback or ‘‘autoamplification’’ loops
as well as through cross-regulatory inhibition of other lineages.
Until recently, it has been thought that mature CD4+ effector
T cells are inherently stable and do not develop via, and are resis-
tant to, interconversion. However, several studies have now
convincingly demonstrated Treg-to-Th17 and Th17-to-Th1 tran-
sitions (Lee et al., 2009a; Zhou et al., 2009).
Classical Th1 cells develop in response to antigens of intracel-
lular bacteria and viruses through a program that involves
sequential activation of signal transducer of activated T cells
(STAT)-1 and STAT4 by type I and II interferons (IFNa, IFNb,
and IFNg, respectively) and IL-12 (Murphy et al., 2000). This
promotes induction of T-box transcription factor expressed in
T cells (T-bet) and IFNg, the signature transcription factor
and cytokine, respectively, of the Th1 lineage. Th1 cells are
distinguished from other effector lineages by surface expression
of CCR1 and CCR5, as well as CXCR3, which allows trafficking
of differentiated Th1 cells to inflammatory beds. IL-27, a
member of the IL-12 cytokine family that can also induce
expression of T-bet in a STAT1-dependent manner (Kamiya
et al., 2004; Takeda et al., 2003), has emerged as a possible
player in Th1 differentiation, particularly in the intestines (dis-
cussed below).
Th2 cells develop primarily in response to parasitic helminthes
that promote innate immune cell production of IL-4, which
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fying transcription factor GATA3 (Ansel et al., 2006). Th2 cells are
characterized by their production of the cytokines IL-4, IL-5, and
IL-13 and the chemokine receptors CCR3 and CCR4 (O’Garra
et al., 1998). Although not considered classical Th2 cells, a
distinct population of IL-13-producing NKT cells is detectable
in the large intestine of mice and humans, in the context of
some types of IBD (see below).
Th17 cells appear specialized for responses to extracellular
bacteria and fungi, and their differentiation is induced by
combined actions of TGF-b and IL-6, which induce sequential
recruitment of STAT3 and retinoic acid receptor-related orphan
nuclear receptor (ROR)gt (Weaver et al., 2007), albeit in cooper-
ation with other transcription factors (Brustle et al., 2007; Quin-
tana et al., 2008; Schraml et al., 2009; Veldhoen et al., 2008a;
Yang et al., 2008b). IL-17A and IL-17F are characteristic of
Th17 cells and promote neutrophil development and recruit-
ment, and enhanced epithelial barrier function. IL-22, another
Th17 cytokine, is important in intestinal epithelial barrier function
(Zheng et al., 2007). IL-21 can act as an autocrine growth factor
for Th17 cells, although it is not unique to this CD4+ lineage. Th17
cells coexpress CCR6 and CCR4 (Acosta-Rodriguez et al.,
2007), but despite their preferential accumulation in the intes-
tines at steady state, no association has beenmade with homing
molecules unique to the gut. In fact, retinoic acid, which induces
gut tropism in activated T cells, inhibits Th17 development
(Mucida et al., 2007), leaving open the question of what controls
gut-specific Th17 homing. Developing Th17 cells acquire
responsiveness to the IL-12 family cytokine, IL-23, through upre-
gulation of the inducible component of the IL-23 receptor
(IL-23R) (Weaver et al., 2006). Although precise functions of
IL-23 remain to be defined, IL-23 appears critical for late devel-
opmental functions of Th17 cells that are essential for their
immune-effector activity and pathogenicity (McGeachy et al.,
2007; McGeachy et al., 2009).
Recent reports have proposed the existence of a fourth subset
of effector CD4+ T cells, referred to as ‘‘Th9’’ cells, which are
characterized by the production of IL-9 and can be induced by
treatment of Th2 cells with TGF-b or by antigenic stimulation of
naive T cells in the presence of TGF-b and IL-4 (Dardalhon
et al., 2008; Veldhoen et al., 2008b). However, although these
cells lack expression of transcription factors typical of other
effector lineages, no lineage specification factors have yet
been defined for this subset, and IL-9 can also be induced in
Th17 and Treg cells (Elyaman et al., 2009; Lu et al., 2006; Nowak
et al., 2009). Definitive designation of Th9 as a distinct lineage
awaits further studies.
Development of Effector T Cells Is Favored
in the Intestines at Steady State
The GALT of the normal intestines includes both effector and
regulatory T cell subsets. Because at homeostasis T cell-medi-
ated immune suppression appears to be the default pathway,
the normal intestinal lamina propria and its associated lymphoid
follicles are home to a large number and relatively high frequency
of Foxp3- and/or IL-10-expressing CD4+ T cells (Kamanaka
et al., 2006; Maynard et al., 2007; Uhlig et al., 2006). However,
Th1 and Th17 cells are also detectable in the uninflamed intes-
tinal lamina propria, in greater numbers than perhaps any othertissue site. The fact that IL-10-producing cells develop alongside
all known effector lineages, coupled with increased frequencies
of Th1 and Th17 cells in IL-10-deficientmice, suggest a dominant
role for IL-10-expressing CD4+ T cells in suppressing intestinal
effector T cell development and function and is consistent with
the spontaneous development of colitis under conditions of
genetic deficiency of IL-10 production by CD4+ T cells (Roers
et al., 2004).
In contrast to Th1 and Th17 cells, Th2 cells are rare or absent
from the normal, uninfected intestines. In view of the role of Th2
cells in coordinating host responses to parasitic helminthes and
the relative scarcity of these organisms in the intestinal flora of
specific pathogen-free mice and humans living in countries with
good sanitation, this is perhaps not surprising. Although in early
reports Th2 cells were found in abundance in the intestines of
mice (Taguchi et al., 1990), in retrospect, this likely reflected the
presence of intestinal parasites in the mouse colonies studied.
Thus, mice raised in pathogen-free environments are essentially
devoid of intestinal Th2 cells until infected with helminths, in
accordance the observed absence of IL-4 production by intes-
tinal DCs that produce basal amounts of proinflammatory cyto-
kines that drive Th1 and Th17 responses (Artis et al., 2005).
Development of, or Divergence to, Intestinal Th1 Cells
in the Steady State
Th1 cells are normally present in both the small and large intes-
tines. Early studies of IL-12 family cytokines found significant
expression of mRNA encoding IL-12p40, particularly in the
terminal ileum (Becker et al., 2003), suggesting that IL-12 might
drive Th1 cell differentiation. It has also been demonstrated that
IL-23 is more highly expressed by intestinal APCs, whereas
IL-12 is predominant from APCs of peripheral lymphoid tissues,
suchas spleen (Hueet al., 2006). Although IL-23canelicit produc-
tion of IFNg from memory CD4+ T cells (Oppmann et al., 2000), it
does not drive classical Th1 differentiation. Collectively, these
data suggest that ‘‘Th1’’ cellsdetectable in the intestinesat steady
statemight develop via an IL-23-dependent pathway, develop via
an alternative, IL-12-independent pathway, or migrate there
following induction in peripheral lymphoid tissues (Figure 2).
Although the source of Th1-type cells in the normal GALT is
currently unclear, it is now apparent that developing Th17 cells
can retain responsiveness to IL-12 and be deviated to a Th1
phenotype late in their development, and at low concentrations
of TGF-b, can also deviate to a Th1-like phenotype in the pres-
ence of IL-23 and absence of IL-12 (see below). Alternatively,
IL-27R-deficient mice display substantially reduced frequencies
of IFNg-expressing CD4+ T cells in the intestinal lamina propria
(Troy et al., 2009). Further, IL-27-deficiency is associated with
elevated expression of IL-17 in the intestines, consistent with
the reported ability of this IL-12 family member to inhibit Th17
differentiation (Batten et al., 2006; Stumhofer et al., 2006). Thus,
IL-27 might favor intestinal Th1 development while suppressing
Th17 development. However, IL-27 also promotes IL-10 expres-
sion in CD4+ T cells and could thus modulate intestinal effector
cell homeostasis through indirect, IL-10-dependent effects that
favor reciprocal Th1 and Th17 differentiation. None of these
mechanisms is mutually exclusive, and a complete under-
standing of the developmental origins of Th1-type effectors in
the intestinal tissues awaits further study.Immunity 31, September 18, 2009 ª2009 Elsevier Inc. 391
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Figure 2. Possible Mechanisms of Induction
and Control of Intestinal T Cell Lineage
Development
Activation of intestinal APCs by commensal
microbes acquired by direct sampling of the
luminal contents or via ingestion of transcytosed
or invading microbes results in secretion of proin-
flammatory cytokines, such as IL-6, IL-23, and
IL-27. Along with TGF-b, IL-6 induces differentia-
tion of a population of Foxp3 and RORgt ‘‘double-
positive precursor’’ cells, which express low
amounts of both transcription factors. Sustained
or increased TGF-b stimulation coupled with
reduced IL-6 signaling in the presence of retinoic
acid (RA) skews this population toward increased,
stable expression of Foxp3 and downregulation of
RORgt and the Th17 program. Conversely, lower
amounts of TGF-b signaling in the continued pres-
ence of IL-6 favor downregulation of Foxp3 and
divergence toward RORgt-expressing Th17 cells.
IL-27 can inhibit Th17 development while directly
promoting STAT1-driven differentiation of Th1
effectors. IL-23 produced by TLR- and/or NLR-
activated APCs promotes late stages of proinflam-
matory Th17 effector functions. Intestinal Th1 cells
might emerge from Th17 precursors or develop
independently of the Th17 pathway. Commensal
antigen stimulation of IECs induces expression of
TSLP and IL-25, which can inhibit Th17 mainte-
nance by suppressing local expression of IL-23.Steady-State Intestinal Th17 Cells: Current Concepts
and Controversies
The enrichment of Th17 cells in the intestinal lamina propria
compared to other tissues suggests a role for the commensal
flora in the differentiation of this subset, although studies exam-
ining this issue have produced conflicting results. In one recent
study, the presence of Th17 cells in the SI lamina propria was
dependent on commensal microbiota, because mice raised
under germ-free conditions were essentially devoid of Th17 cells
and mice of the same genetic strain raised in distinct environ-
ments displayed different frequencies of Th17 cells (Ivanov
et al., 2008). However, these findings were contradicted by an
independent report showing that germ-free mice have normal
levels of Th17 cells in the SI lamina propria (Zaph et al., 2008).
There have also been reports of the intestinal microbiota both
promoting (Atarashi et al., 2008) and suppressing (Zaph et al.,
2008) colonic Th17 cell development. The basis for these con-
flicting results is currently unclear.
Normal frequencies of Th17 cells were present in the small
intestine of mice lacking key adaptor proteins critical for
signaling in the toll-like receptor (TLR) system (Myd88 and
TRIF), suggesting that although the commensal microbiota
may be critical for intestinal Th17 development, the mechanism
can be TLR independent (Atarashi et al., 2008; Ivanov et al.,
2008). Yet, mice deficient for TLR9, which requires MyD88 for
signaling, have reduced frequencies of IL-17+CD4+ T cells in
the SI lamina propria (Hall et al., 2008). The reasons for these
apparent discrepancies are not known, but it appears that the
relationship between innate sensing of the intestinal microbiota
and stimulation of Th17 development at steady state may be
complex and is likely multifactorial.
The transcription factors and cytokines important for Th17
development have begun to be studied in the context of the
intestines. The transcription factor RORgt is required for optimal392 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.development of Th17 cells in the small intestines (Ivanov et al.,
2006). However, small numbers of Th17 cells persist in RORgt-
deficient mice and most likely develop through utilization of the
second Th17-associated ROR family member, RORa (Yang
et al., 2008b). To date, there have been no reports examining
Th17 development in the intestines of mice with deficiencies of
other transcription factors important for Th17 development
(e.g., IRF4, AhR, and Batf).
TGF-b is abundant in the intestines, where it is produced by
epithelial cells, as well as innate and adaptive immune cells.
Consistent with in vitro findings, TGF-b appears to be required
for intestinal Th17 development because mice with TGF-b1 defi-
ciency or defective TGF-b activation restricted to the extracel-
lular matrix lacked intestinal Th17 cells (Ivanov et al., 2008; Man-
gan et al., 2006). It should be noted, however, that studies to date
do not exclude the possibility that reduced frequencies of Th17
cells observed in the absence of active TGF-b are due in part
to inhibition of Th17 development by the increased amounts of
IFNg present in mice with defective TGF-b function.
The majority of TGF-b in the intestines is associated with the
extracellular matrix in latent form, and multiple cell types can
release active TGF-b—and through multiple mechanisms.
Notably, however, DCs that express the latent TGF-b-binding
integrin, avb8 (Mu et al., 2002), can release active TGF-b, which
appears to play an important role in TGFb regulation in the intes-
tines (Travis et al., 2007). The lamina propria of the small intes-
tines harbors a population of CD11chiCD11b+CD103loCX3CR1hi
DCs that preferentially induce IL-17 in CD4+ T cells via a mecha-
nism that is at least partially dependent on TGF-b (Denning et al.,
2007), and in the lamina propria of the large intestine, a popula-
tion of CD11loCD70hi DCs that harnesses commensal-derived
adenosine triphosphate (ATP) to drive Th17 development
expresses avb8 (Atarashi et al., 2008). Thus, although specific
cell populations and mechanisms by which active TGF-b is
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Mouse Model Tissue Affected Histology Resembles Effector T Cells Detected References
T cell transfer Colon CD Th1, Th17 (Izcue et al., 2008; Morrissey et al., 1993;
Powrie et al., 1993; Powrie et al., 1994)
IL-10-deficient Colon CD Th1, Th17 (Kuhn et al., 1993; Yen et al., 2006)
STAT-4 transgenic Colon CD Th1 (Wirtz et al., 1999)
C3H/HeJBir Cecum CD Th1, Th17 (Cong et al., 1998; Sundberg et al., 1994)
SAMP1/Yit Distal SI CD Th1, Th2 (Kosiewicz et al., 2001; Matsumoto et al., 1998)
TNBS Colitis Colon CD Th1, Th17 (Alex et al., 2009; Strober et al., 2002)
Chronic DSS Colitis Colon UC Th1, Th2, Th17 (Dieleman et al., 1998; Takedatsu et al., 2008)
Oxazolone Colitis Colon UC Th2, NKT Cells (Boirivant et al., 1998; Heller et al., 2002)
TCRa-deficient Colon UC ‘‘Th1,’’ ‘‘Th2’’ (Mizoguchi et al., 1996; Mombaerts et al., 1993;
Nishiyori et al., 2009)generated to drive induction of Th17 cells remain to be fully char-
acterized, it is likely that DCs expressing avb8 integrin play an
important role in the intestines.
To our knowledge, there have been no reports on the status of
Th17 cells in intestinal tissues of mice deficient for IL-6, although
given its central role in Th17 development and the production of
IL-6 by intestinal DCs (Hart et al., 2005), it is presumed that
steady-state Th17 development is dependent on IL-6. However,
despite the reported requirement for autocrine IL-21 in optimal
Th17 development ex vivo, Th17 frequencies in the SI lamina
propria appeared to be enhanced in the absence of IL-21 (Ivanov
et al., 2008). This is in contrast to peripheral lymphoid tissues
where deficient IL-21 signaling was reported to reduce the
number of IL-17+ memory CD4+ T cells (Korn et al., 2007).
Notably, IL-21 also promotes induction of IL-10 (Maynard
et al., 2009; Pot et al., 2009; Spolski et al., 2009), and it is
possible that particularly in the steady-state intestines, this func-
tion of IL-21 is dominant such that enhanced frequencies of Th17
cells associated with IL-21 deficiency might result from reduced
suppression by IL-10.
A role, if any, for IL-23 in regulating the numbers of intestinal
Th17 cells at steady state is largely unresolved. The frequency
of Th17 cells in the small intestines, as well as the degree of
IL-17 expression there, appeared to be only slightly diminished
in the absence of IL-23 (Ivanov et al., 2008). Similarly, Th17 cells
were present in the large intestine of uninfected IL-23-deficient
mice, which also mounted a robust Th17 response to infection
with Citrobacter rodentium (Mangan et al., 2006), suggesting
that IL-23 is dispensable for Th17 development in the large intes-
tine in the steady state or in response to infection. In contrast,
commensal-dependent production of IL-25 by intestinal epithe-
lial cells results in reduced numbers of Th17 cells in the lamina
propria of the large, but not the small, intestine through sup-
pressed induction of IL-23 (Zaph et al., 2008). Indeed, compared
to wild-type mice, IL-25-deficient mice have increased Il23p19
transcripts and a corresponding increase in IL-17+ cells in the
large intestine (Zaph et al., 2008).
Effector T Cells in IBD: Lessons from Animal Models
and Human Correlates
Due to limitations inherent to immune studies of human popula-
tions, much of our current understanding of the pathogeneticbasis for IBD has been derived from studies of mouse models,
which have provided important insights into the development
of distinct effector populations and how these pathways con-
tribute to IBD. There is still no animal model that is a perfect phe-
nocopy for human IBD, particularly with respect to one of the
least understood aspects of human disease—the characteristic
cycles of relapse and remission typical of the clinical course in
many IBD patients. Instead, most mouse models involve either
an acute disease that resolves spontaneously or a chronic, non-
remitting disease that eventually results in death of the animal.
Also, most models are heavily biased toward inflammation of
the large intestine (Table 1). Nevertheless, animal models of
IBD have been invaluable in defining pathogenic mechanisms
and offer the advantage of facilitating study of defined alterations
in host barrier function, innate immunity, and adaptive immunity
or alterations of the intestinal microbiota that impact develop-
ment of intestinal inflammation (Elson et al., 2005).
Whereas a number of mouse models with germline defi-
ciencies of genes linked to immune regulation result in intestinal
inflammation, many of these models also induce multiorgan
inflammation. These include mice with targeted deficiencies of
the genes encoding IL-2, IL-2 receptor, TGF-b, TGF-b receptor II,
SMAD3, and A20, as well as CD40 ligand transgenic and TNF-a
gene-targeted (TnfDARE/DARE) mice. Here, we highlight those
models in which disease is primarily restricted to the intestinal
tissues and is dependent on effector T cell responses for induc-
tion, perpetuation, or both (Table 1) and discuss correlates with
human IBD.
Crohn’s Disease: Th1, Th17, or Both?
Although Crohn’s disease andmousemodels that share features
with CD were originally attributed to Th1-mediated pathogen-
esis, the recent emergence of the Th17 lineage has precipitated
a reassessment of its immune-based etiology. The discovery of
IL-23 and its subsequent link to induction of IL-17 cytokines and
the Th17 pathway resulted in a re-examination of the relative
roles of the Th1-asssociated IL-12-IFNg inflammatory axis
and the new, Th17-associated IL-23-IL-17 axis in multiple auto-
immune and chronic inflammatory diseases, including IBD.
Because IL-12 and IL-23 are heterodimeric cytokines that share
the IL-12p40 subunit, and the majority of studies predating IL-23
and Th17 that examined the role of IL-12 in IBD pathogenesisImmunity 31, September 18, 2009 ª2009 Elsevier Inc. 393
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the observed disease-ameliorating effects were due to IL-12,
IL-23, or both. This, coupled with increases of both Th1 and
Th17 cells in inflamed colons of both mice and humans, sug-
gested that Th17 cells might also be key players in IBD.
In both the CD45RBhi T cell transfer and IL-10-deficient
models of colitis, early studies showed that development of
colitis was almost completely abrogated by early treatment
with IFNg-blocking antibody, consistent with a Th1-mediated
pathogenesis (Berg et al., 1996; Powrie et al., 1994). In one
report, disease did not develop in the transfer model if CD4+
T cells were isolated from IFNg-deficient donors (Ito and Fath-
man, 1997). In support of a Th1 pathogenesis, transfer of
T cells deficient for the Th1-associated transcription factor,
T-bet, failed to induce disease, whereas adoptive transfer
of T-bet-transduced T cells resulted in colitis in recipient mice
(Neurath et al., 2002). Further, T cells deficient in the Th1-asso-
ciated differentiation factor, STAT4, produced substantially
reduced disease following transfer (Simpson et al., 1998). In
conflict with a strictly Th1 pathogenesis, however, the transfer
of IFNg-deficient CD4+CD45RBhi T cells did induce colitis in
one study (Simpson et al., 1998), suggesting the involvement
of either an IFNg-independent Th1-type program or a distinct
effector pathway. Consistent with the latter observation, H. hep-
aticus-induced colitis developed in mice doubly deficient for
IL-10 and IFNg comparable to that of IL-10-deficient mice (Kull-
berg et al., 2001), demonstrating that IFNg was dispensable for
disease onset.
As in mouse IBD models, CD was initially postulated to result
from a dysregulated Th1 response, based on elevated frequen-
cies of IFNg- and T-bet-expressing CD4+ T cells in diseased
intestinal tissues (Fuss et al., 1996; Matsuoka et al., 2004; Neu-
rath et al., 2002). Increased serum IFNg was also detected in
CD patients, but not in UC patients or normal controls (Beltran
et al., 2009). Moreover, expression of both chains of the IL-12
receptor (IL12Rb1 and IL-12Rb2) and the IL-18R, features of
mature Th1 cells, were upregulated on lamina propria CD4+
T cells of CD patients and enabled enhanced production of
IFNg when the cells were activated ex vivo with IL-12 and
IL-18 (Okazawa et al., 2002). Finally, although antibody blockade
of IFNg has shown limited effectiveness in IBD patients, consis-
tent with its limited effectiveness in established disease in mice,
treatment with anti-human ‘‘IL-12’’ (in fact, an IL-12p40mAb that
neutralizes both IL-12 and IL-23) has shown substantial efficacy
in active CD (Mannon et al., 2004). Although originally offered as
evidence in support of a Th1 etiology of CD, recent mouse data
demonstrating greater treatment efficacy by interruption of IL-23
rather than IL-12 signaling (see below) has weakened a strict Th1
link in CD.
Although findings implicating factors associated with the Th1
effector pathway in models of CD cannot be ignored, studies
that have come in the wake of the discovery of Th17 have
increasingly implicated a dominant role for Th17 cells in disease
pathogenesis. In addition to the IFNg-producing cells described
in early studies, a sizeable fraction of CD4+ T cells recovered
from mucosal compartments in diseased mice of CD45RBhi
T cell transfer and IL-10-deficient models are a distinct subset
of IL-17-producing CD4+ T cells, as well as some ‘‘double
producers’’ that express both IL-17 and IFNg (Izcue et al.,394 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.2008; Yen et al., 2006). Importantly, adoptive transfers of intes-
tinal bacteria-reactive Th17 cells into immunodeficient recipients
induced more severe colitis than comparable transfers of Th1
cells and induced disease at far lower cell doses (Elson et al.,
2007), analogous to earlier findings in a model of EAE (Langrish
et al., 2005). Treatment with an IL-23p19 monoclonal antibody
inhibited colitis development when administered at the time of
transfer but also suppressed ongoing disease and resulted in
the depletion of the transferred Th17 effectors, indicating that
IL-23 is required to sustain the pathogenic Th17 population
(Elson et al., 2007). Further, deletion of the gene encoding
IL-23p19, but, importantly, not IL-12p35, inhibited spontaneous
colitis in IL-10-deficient mice, proving that IL-23, and not IL-12, is
necessary for the spontaneous colitis that develops in this model
(Yen et al., 2006). Moreover, treatment with IL-23 accelerated
disease onset in RAG-deficient recipients of memory T cells har-
vested from IL-10-deficient mice. Collectively, these data
strongly implicate IL-23-dependent Th17 effector mechanisms
in the development of intestinal inflammation.
Other animal studies have recently examined possible contri-
butions of additional components of the Th17 pathway in IBD
pathogenesis. Antagonism of IL-6 receptor signaling, or transfer
of cells deficient for interferon regulatory factor (IRF)-4—a tran-
scription factor implicated in Th17 differentiation—blocked
induction of colitis in a T cell transfer model. Interestingly, colitis
that was indistinguishable from that induced by wild-type T cells
developed in RAG-deficient recipients of naive T cells isolated
from Il17a/, Il17f/, or Il22/ mice (Izcue et al., 2008; Lep-
pkes et al., 2009). However, transfer of Il17f/ T cells with
concomitant neutralization of IL-17A resulted in reduced disease
severity, as did transfer of RORgt-deficient naive T cells, sug-
gesting that RORgt-directed IL-17A and IL-17F redundantly
drive inflammation in this model (Leppkes et al., 2009). This is
at apparent odds with earlier experiments showing that T-bet
deficiency, IFNg deficiency, or blockade of IFNg is sufficient to
prevent colitis in this model (Berg et al., 1996; Neurath et al.,
2002; Powrie et al., 1994) and with a recent report demonstrating
enhanced kinetics of wasting disease in recipients of Il17a/
T cells compared to recipients of wild-type T cells (O’Connor
et al., 2009). This latter study suggests a regulatory role for
IL-17A early in disease development, and the authors propose
that this is achieved via suppression of IFNg production from
Th1 effectors, implicating Th1 cells as key culprits in disease
onset, consistent with earlier reports. However, none of the
histological parameters of experimental colitis were different
between recipients of wild-type and Il17a/ T cells, and thus,
any IL-17-mediated protection appears to be readily overcome
by the early Th1 burst.
Predating discovery of the Th17 lineage, elevated expression
of IL-17A by CD3+ lymphocytes and CD68+ macrophages or
monocytes was found in intestinal tissues of CD and UC patients
compared to normal patients or patients with infectious or
ischemic colitis (Fujino et al., 2003). Although IL-17A+ lympho-
cytes were readily detectable in both CD and UC lesions, the
frequencies were higher in CD and correlated with disease
activity and serum IL-17A. A different picture emerged when
intestinal transcripts of Il17f, the other IL-17 family member
produced by Th17 cells, were measured. Although Il17f mRNA
was elevated in inflamed versus noninflamed biopsies from the
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from UC patients in comparison to CD patients (Seiderer et al.,
2008). However, further work will be necessary to define the
contribution of IL-17F in human IBD.
Whether Th1 cells, Th17 cells, or both are required for exper-
imental colitis continues to be contentious because there is
experimental evidence supporting the pathogenicity of each
population, although this varies between models and in some
instances, between laboratories studying the same models.
Nevertheless, it is clear that cells competent for expression of
both IFNg and IL-17 are detectable at all stages of disease in
T cell-dependent mouse models, as well as in human CD. The
fact that early, but not late, blockade of IFNg prevents disease
suggests that IFNg might be more critical for disease onset
than for its persistence. Alternatively, it is possible that other
T-bet- and STAT4-dependent aspects of the Th1 pathway can
compensate for critical functions of IFNg. T-bet is believed to
promote the pathogenic potential of both Th1 and Th17 in other
models of autoimmunity, such as EAE (Yang et al., 2009), and
might function in a similar manner in IBD. Finally, recent studies
by our group and others have demonstrated developmental
plasticity in the Th17 pathway that enables Th17 cells to divert
to IFNg production in the context of colitis (see below) (Annun-
ziato et al., 2007; Lee et al., 2009b; Lexberg et al., 2008), offering
the possibility of a pathogenetic mechanism that involves IL-17-
and IFNg-producing T cells that arise from a common develop-
mental pathway.
Ulcerative Colitis: A Role for Th2 and Th2-like Cells?
In contrast to CD, the absence of elevated IFNg in UC patients
fueled early speculation that perhaps the other T effector lineage
then known (Th2) might be involved in disease pathogenesis
(Niessner and Volk, 1995). However, direct data in support of
a Th2 etiology were lacking. In fact, IL-4-expressing T cells
were reduced in IBD patients compared to healthy controls,
although IL-5 was shown to be increased in UC patients com-
pared to CD patients and normal controls (Fuss et al., 1996). It
was later found that whereas there were no major differences
in Il4 and Il13mRNA expression between UC patients with inac-
tive disease and controls, both transcripts were elevated in
active UC lamina propria cells. Interestingly, in studies that
corroborated the elevated IL-5 and IL-13 secretion by lamina
propria cells from UC patients, it was also shown that the major
source of the increased IL-13 was a population of CD1d-
restricted NKT cells (Fuss et al., 2004).
Despite the ongoing association of UC with Th2-type
responses—or at least Th2 cytokines—mechanisms involved
in the pathogenesis of UC have been limited by the paucity of
suitable animal models. The oxazolone challenge model was
originally characterized as an acute, Th2-dependent model that
displayed certain hallmarks of UC with the caveat that, unlike
UC, colitis in this model resolves spontaneously and does not
recur (Boirivant et al., 1998). The early inflammatory infiltrate in
this model is characterized by IL-4-, IL-5-, and IL-13-secreting
CD4+ T cells, and importantly, systemic administration of anti-
IL-4 suppresses disease (Boirivant et al., 1998). Confirming the
importance of effector T cell differentiation in this model, mice
deficient for IRF-4 develop minimal disease (Mudter et al.,
2008), although a caveat here is the recent association ofIRF-4 with Th17 development in addition to Th2 development
(Brustle et al., 2007). In this regard, disease development is
also impeded in the absence of IL-6, a known inducer of Th2
and Th17 cell differentiation (Weigmann et al., 2008).
In subsequent studies of a more chronic variant of the oxaz-
alone model, it was found that an IL-4-dependent early phase
of intestinal inflammation was superseded by an IL-13-domi-
nated late phase. The major source of IL-13 was identified as
a ‘‘nonclassical’’ NKT cell that is restricted by theMHCmolecule,
CD1d, but unresponsive to the invariant NKT ligand, a-galacto-
sylceramide (Fuss et al., 2004). Accordingly, depletion of NK
and NKT cells prior to oxazolone treatment, as well as inhibition
of CD1d antigen presentation to NKT cells, prevented the devel-
opment of disease (Heller et al., 2002). It is still unknown how
IL-13 is induced in this model, except that CD1d-restricted
antigen presentation is required. It is also unknown how early
induction of IL-4 is linked to disease development and pro-
gression.
Although not readily detectable at steady state, Th2 cell
responses are rapidly induced in the intestines of mice infected
with parasitic worms. Most models involve immune-mediated
worm expulsion and resolution of inflammation in contrast to
the chronic relapsing and remitting inflammation associated
with UC. However, these studies have identified key mecha-
nisms that contribute to the initiation and resolution of type 2
inflammation in intestinal tissues, and although it is still unknown
whether any of these mechanisms contribute to the Th2-type
responses associated with UC, mechanistic insights from these
studies could prove informative.
Worm infections result in activation of intestinal epithelial cells
(IEC) to produce thymic stromal lymphopoietin (TSLP), which
promotes parasite-specific Th2 responses in mucosal tissues
(Zaph et al., 2007). TSLP-activated DCs upregulate the Th2-at-
tracting chemokines thymus and activation-regulated chemo-
kine (TARC or CCL17) and MDC macrophage-derived chemo-
kine (MDC or CCL22) and induce Th2 differentiation (Soumelis
et al., 2002; Zhou et al., 2005), suggesting that TSLP directly
drives Th2 responses. However, Th2 cells still develop in the
absence of TSLP signaling, especially if IFNg is neutralized
(Ramalingam et al., 2009; Taylor et al., 2009). Thus, elevated
expression of Th1- and Th17-associated cytokines in parasite-
infected Tslpr/ mice, and the resultant defect in Th2
responses, suggest that TSLP might be more critical for sup-
pression of IL-12- and IL-23-dependent responses in the intes-
tine, thereby allowing for the initiation of type 2 immunity (Taylor
et al., 2009; Zaph et al., 2007).
IL-25 is constitutively expressed in the intestines, contingent
on the presence of a commensal flora, and is, therefore, more
highly expressed in the large intestines than any other tissue
(Zaph et al., 2008). IL-25 treatment induces heightened expres-
sion of the Th2 effector cytokines IL-5 and IL-13 (Fort et al.,
2001), both prominent in human UC, and IL-25 was recently
shown to inhibit IL-23-dependent responses in the colon (Zaph
et al., 2008). Thus, IL-25 and TSLP appear to perform redundant
and nonredundant roles in type 2 immune responses to parasite
infection. In this regard, it was recently reported that TSLP
induced by intestinal helminth infection promotes the rapid
recruitment of basophils, which act both as the primary APC
and source of IL-4 to initiate Th2 responses (Perrigoue et al.,Immunity 31, September 18, 2009 ª2009 Elsevier Inc. 395
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inflammation. Although it is unclear at present whether IL-25 and
TSLP contribute to oxazalone-induced colitis, have links to UC
pathogenesis, promote development and function of nonclas-
sical NKT cells, or whether basophils are central to immune path-
ogenesis, these studies suggest mechanisms to be explored in
the context of Th2-type intestinal inflammation and IBD.
Immunological ‘‘Flip-Floppers’’: Lineage Plasticity
of Effector and Regulatory T Cells and Possible
Implications for IBD
Several recent studies have unveiled a previously unappreciated
feature of CD4+ T cell biology that promises to impact IBD
immune pathogenesis—lineage plasticity among effector and
regulatory T cell lineages (Lee et al., 2009a; Zhou et al., 2009).
CD4+ T cells expressing both Foxp3 and RORgt have been
detected in the normal intestines of both mice and humans,
residing alongside subsets that express one or the other of these
factors (Miyara et al., 2009; Yang et al., 2008a; Zhou et al., 2008).
It is currently unknown whether these ‘‘dual expressors’’ repre-
sent the earliest precursors of Th17 or Treg cells, each of which
have been shown in vitro to express both RORgt and Foxp3 prior
to extinction of the opposing factor (Zhou et al., 2008); whether
these cells represent fully differentiated Foxp3+ Treg cells transi-
tioning to Th17 cells in response proinflammatory cytokines; or
both. However, this finding raises the intriguing possibility that
CD4+ T cells that differentiate in or localize to the intestines retain
developmental and functional flexibility to facilitate adjustment
to this dynamic environment. The transition of Tregs to Th17
progeny might not be unique, as a recent study provides
evidence that Tregs might also acquire Th1 effector features in
response to Th1 polarizing cytokine conditions (Wei et al.,
2009). It is currently unclear whether similar transitions might
occur in the inflamed intestines and if so, what the implications
are for regulatory control in IBD.
If the developmental plasticity of Tregs in the intestines
remains largely speculative, that of Th17 cells is not. Th17 cells
defined by an IL-17F reporter transgene could diverge into
distinct progeny contingent upon the balance of TGF-b, IL-23,
and IL-12 (Lee et al., 2009b). Importantly, the transition of a
subset of Th17 precursors to Th1-type cells was associated
with the development of colitis following transfer of Th17 cells
into immunodeficient recipients, resulting in a population of
intestinal effector T cells with mixed Th17 and Th1 phenotypes
similar to that found in CD45RBhi transfer controls. In a comple-
mentary study, it was found that memory Th17 cells isolated
from the mesenteric lymph nodes of normal mice were resistant
to transition to Th1 cells (Lexberg et al., 2008), implying that
under certain conditions, the Th17 program becomes fixed
through mechanisms yet to be defined. These findings might
explain the paired coexistence of Th1- and Th17-type cells in
intestinal tissues—at homeostasis and in IBD—without invoking
independent, parallel development of Th1 and Th17 lineages.
Flexibility in the late Th17 developmental program appears to
be shared in man. CD4+ T cells isolated from the intestinal
mucosa of CD patients demonstrated distinct subsets of Th1
and Th17 cells, as well as IL-17 and IFNg double-expressing
CD4+ T cells (Annunziato et al., 2007), analogous to findings in
mouse models of CD, and Th17 and ‘‘Th17-Th1’’ cells cloned396 Immunity 31, September 18, 2009 ª2009 Elsevier Inc.from intestinal isolates were diverted to a Th1 phenotype in
response to IL-12. More recently, the expression of the NKT
cell marker CD161 has been linked to Th17 cells present in
healthy and chronically inflamed patients (Cosmi et al., 2008;
Kleinschek et al., 2009). Notably, CD161 also identifies a sizeable
fraction of IFNg-producers (even larger than the IL-17+ subset).
Thus, although initially proposed as a marker for human Th17
cells, CD161 marks precursors that, in response to IL-1 and
IL-23—conditions that favor development of human Th17
cells—also give rise to an important, distinct population of
IFNg+ cells, suggesting that this marker might be common to
precursors predisposed to both Th17 and Th1 phenotypes in
response to Th17-promoting signals (Cosmi et al., 2008). Thus,
it appears that differentiating and early effector Th17 cells are
phenotypically unstable and responsive to multiple stimuli that
define their late developmental path. The impact of these
phenomena on IBD development and persistence are likely to
be important but remains to be defined.
Concluding Remarks
There are multiple pathophysiologic pathways that can culmi-
nate in the diseases that we recognize as CD or UC. Animal
studies have established that dysregulated effector T cell
responses to the commensal flora can be causative in IBD and
likely represent a final, common immunopathogenetic mecha-
nism in most, if not all, forms of IBD, irrespective of the inciting
events that promote them. Remarkably, evidence for conserved
recognition of a group of immunodominant commensal microbial
antigens that is shared by a subset of patients with CD and mice
with IBD, particularly bacterial flagellins, provides evidence sup-
porting a common, microbiota-driven disease mechanism in
human IBD (Lodes et al., 2004). Given that the pool of microbial
antigens encoded by the collective genome of the commensal
microbiota far outstrips that encoded by the host genome and
coexists in the host from soon after birth until death, it is remark-
able that IBD is notmore common. It is a testament to the robust-
ness of normal barrier, innate and regulatory adaptive immune
responses to the microbiota that these antigens are largely
sequestered in the gut lumen and that homeostasis in the intes-
tinal tract is in fact the norm.
Alternatively, given the antigenic diversity and immune stimu-
latory potential of the commensal microbiota and its intrinsic
feeding of the extracellular antigen processing pathways linked
to MHC II and certain nonclassical MHCs (eg, CD1d), it is
perhaps not surprising that each of the well-defined CD4+
effector T cell lineages (Th1, Th2, and Th17), as well as NKT
effectors, have been implicated in some form of IBD. The chal-
lenge now before us will be to better define which effector path-
way(s) is active in specific forms of IBD, indeed, in individual
patients, and to determine how theymight be best brought under
control.
As reflected in the studies highlighted herein, even in geneti-
cally defined animal models, there remains considerable contro-
versy over which effector responses are involved and how, even
if there is consensus over the central role played by effector
T cells. Although the power of animal models, and in particular,
the inbred, genetically defined—and genetically manipulable—
mouse, has proven invaluable in getting us this far, it is likely
that animal models will play an increasingly supportive role going
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Reviewforward. Perhaps ironically, increasingly, it is the remarkably
outbred human that holds the key to best unraveling the patho-
genetic mechanisms important in the complex, polygenic
diseases encompassed within IBD. In this postgenomic era,
the development of high-throughput technologies for defining
microgenetic variations in the outbred human population has
rapidly accelerated discovery of, or confirmation of, important
innate and adaptive immune pathways that predispose to intes-
tinal inflammation—precisely because the more random assort-
ment of genes in outbred populations permits the linking of
susceptibility haplotypes that are rare or nonexistent in inbred
populations. Thus, in the wake of the report of the first two genes
linked to IBD through genome-wide association studies (GWAS),
one representing the innate arm (NOD2-CARD15) and one with
direct connections to the adaptive arm (IL23R), the number
and diversity of susceptibility or protective genetic variations
identified in human IBD cohorts is rapidly accelerating (Cho,
2008; Shih et al., 2008), and genes and pathways that were not
immediately forthcoming from animal studies are being identified
(e.g., the autophagy pathway genes, ATG16L1 and IRGM). Con-
tinued efforts in this vein should ultimately lead to more patient-
specific therapies as the range of disease-susceptibility (and
resistance) genes is more finely mapped and technologies for
efficient, cost-effective patient screening advance. Indeed, it is
likely that immunologists, not just IBD patients, will also reap
the benefits of this information explosion by identifying central
immunomodulatory genes and pathways heretofore unknown.
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